GlassScriptPhysician profile
Diana Zapp
NPI 1508220823
$2,159.69
in general payments reported to CMS, 2019-2025
22 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.35 · 2022: $1,264 · 2023: $259 · 2024: $357 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Cardiovascular Systems Corporation | $1,182.10 | 2022 | |
| Novartis Pharmaceuticals Corporation | $120.40 | 2023-2025 | |
| Silk Road Medical, INC. | $120.34 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Bard Peripheral Vascular, INC. | $91.51 | 2024 | Venovo |
| Shockwave Medical, INC | $71.48 | 2025 | |
| Kerecis Limited | $66.51 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Abbott Laboratories | $60.60 | 2025 | Xience Skypoint, Nc Trek Neo |
| Innocoll Pharmaceuticals Limited | $56.23 | 2021-2022 | |
| Amgen INC. | $54.56 | 2022-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $54.33 | 2023-2025 | Wainua |
| Scpharmaceuticals INC. | $51.48 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $45.60 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Janssen Pharmaceuticals, INC | $30.90 | 2022-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.79 | 2023-2024 | Jardiance |
| Bridgebio Pharma, INC. | $23.11 | 2025 | Attruby |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.19 | 2024 | Bridion |
| Terumo Medical Corporation | $15.43 | 2025 | Angio-Seal |
| Organogenesis INC. | $15.13 | 2023 | Puraply |
| Lexicon Pharmaceuticals, INC. | $14.39 | 2023 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $14.29 | 2022 | |
| Cvrx, INC. | $13.95 | 2022 | |
| Boston Scientific Corporation | $12.37 | 2025 | Enroute Transcarotid Neuroprotection System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Zapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.